Next, we set out to validate the in silico prediction from the in vivo transcriptomic profile of Rheb1Δ/Δ TAM‐MG that mTOR signalling negatively regulates NF‐κB in TAM‐MG and is responsible for the immunosuppressed phenotype in GBM. Here, MTOR is linked to myasthenia gravis.